Cell surface markers detection refers to separation and identification of target cells using analytical methods and processes, such as flow cytometry. Cell surface marker analysis through the usage of technologies, such as flow cytometry, is expected to simplify disease analysis, sample separation, disease diagnosis, and subsequent treatment determination.
Rise in use of cell surface markers in disease diagnostics, rise in prevalence of cancer, increasing adoption of flow cytometry in stem cell research, increasing demand for precision medicine, and technological advances related to increased throughput and automation are major factors expected to drive growth of the global cell surface markers detectionmarket.
For instance, in April 2022, Sysmex Europe, a provider of automated workflow solutions in the disciplines of hematology, urinalysis, and hemostasis, launched Flow Cytometer XF-1600 which has received CE marking, indicating its compliance with the European IVD Regulation and IVD use; establishing a complete solution for flow cytometry laboratories to help them automate and optimize their workflow for a new level of efficiency.
- This report provides in-depth analysis of the global cell surface markers detectionmarket, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cell surface markers detectionmarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Grifols SA, Abbott Laboratories, Sysmex Corporation, Agilent Technologies Inc., Nexcelom Bioscience, Thermo Fisher Scientific Inc., Siemens Healthineers, Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Becton, Dickinson and Company (BD), Qiagen NV, Diasorin SpA (Luminex Corporation), Danaher Corporation (Beckman Coulter Inc.), and IVD Medical Holding Limited (Immucor Inc.), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global cell surface markers detectionmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell surface markers detectionmarket.
-
- Flow Cytometry
- Hematology Analysers
- Cell Imaging Systems
- Reagents and Kits
- Other Products
-
- Disease Diagnosis and Identification
- Drug Discovery
- Other – Research and Academia Applications
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Grifols SA
- Abbott Laboratories
- Sysmex Corporation
- Agilent Technologies Inc.
- Nexcelom Bioscience
- Thermo Fisher Scientific Inc.
- Siemens Healthineers
- Nihon Kohden Corporation
- F. Hoffmann-La Roche Ltd.
- Bio Rad Laboratories Inc.
- Becton, Dickinson and Company (BD)
- Qiagen NV
- Diasorin SpA (Luminex Corporation)
- Danaher Corporation (Beckman Coulter Inc.)
- IVD Medical Holding Limited (Immucor Inc.)
